Are Biological Drugs Safe in Pregnancy?

PUBBLICAZIONI

Are biological drugs safe in pregnancy?

Calligaro A, Hoxha A, Ruffatti A, Punzi L.

Reumatismo. 2015 Mar 31;66(4):304-17.

Plasma exchange effectively removes 52- and 60-kDa anti-Ro/SSA and anti-La/SSB antibodies in pregnant women with congenital heart block.

Tonello M, Ruffatti A, Marson P, Tison T, Marozio L, Hoxha A, De Silvestro G, Punzi L.

Transfusion. 2015 Jul;55(7):1782-6.

Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study.

Del Ross T, Ruffatti A, Visentin MS, Tonello M, Calligaro A, Favaro M, Hoxha A, Punzi L.

J Rheumatol. 2013 Apr;40(4):425-9.

A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature.

Ruffatti A, Marson P, Svaluto-Moreolo G, Marozio L, Tibaldi M, Favaro M, Calligaro A, Grava C, Hoxha A, Pengo V, Punzi L.

Autoimmun Rev. 2013 May;12(7):768-73.

Risk-based secondary prevention of obstetric antiphospholipid syndrome.

Ruffatti A, Calligaro A, Del Ross T, Favaro M, Tonello M, Banzato A, Punzi L, Pengo V.

Lupus. 2012 Jun;21(7):741-3.

Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome.

Bontadi A, Ruffatti A, Marson P, Tison T, Tonello M, Hoxha A, De Silvestro G, Punzi L.

J Clin Apher. 2012;27(4):200-4.

Adjusted prophylactic doses of nadroparin plus low dose aspirin therapy in obstetric antiphospholipid syndrome. A prospective cohort management study.

Ruffatti A, Gervasi MT, Favaro M, Ruffatti AT, Hoxha A, Punzi L.

Clin Exp Rheumatol. 2011 May-Jun;29(3):551-4.

Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome.

Ruffatti A, Calligaro A, Hoxha A, Trevisanuto D, Ruffatti AT, Gervasi MT, Cuffaro S, Pengo V, Punzi L.

Arthritis Care Res (Hoboken). 2010 Mar;62(3):302-7.

PROGETTI

Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study.

Ruffatti A, Salvan E, Del Ross T, Gerosa M, Andreoli L, Maina A, Alijotas-Reig J, De Carolis S, Mekinian A, Bertero MT, Canti V, Brucato A, Bremme K, Ramoni V, Mosca M, Di Poi E, Caramaschi P, Galeazzi M, Tincani A, Trespidi L.

Thromb Haemost. 2014 Oct;112(4):727-35.

The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study.

Mekinian A, Lazzaroni MG, Kuzenko A, Alijotas-Reig J, Ruffatti A, Levy P, Canti V, Bremme K, Bezanahary H, Bertero T, Dhote R, Maurier F, Andreoli L, Benbara A, Tigazin A, Carbillon L, Nicaise-Roland P, Tincani A, Fain O; SNFMI and the European Forum on Antiphospholipid Antibodies.

Autoimmun Rev. 2015 Jun;14(6):498-502.

The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases.

Alijotas-Reig J, Ferrer-Oliveras R, Ruffatti A, Tincani A, Lefkou E, Bertero MT, Coloma-Bazan E, de Carolis S, Espinosa G, Rovere-Querini P, Kuzenko A, Valverde EE, Robles A, Cervera R, Canti V, Fredi M, Gil-Aguado A, Lundelin K, Llurba E, Melnychuk T, Nalli C, Picardo E, Silvestro E, del Ross T, Farran-Codina I; (EUROAPS Study Group Collaborators).

Autoimmun Rev. 2015 May;14(5):387-95.

Anti-Ro/SSA-p200 antibodies in the prediction of congenital heart block. An Italian multicentre cross-sectional study on behalf of the 'Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA) Group'.

Scarsi M, Radice A, Pregnolato F, Ramoni V, Grava C, Bianchi L, Gerosa M, Mosca M, Ghirardello A, Tani C, Motta M, Quinzanini M, Tincani A, Ruffatti A, Migliorini P, Doria A, Meroni PL, Brucato A.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6):848-54.

Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study.

Ruffatti A, Tonello M, Visentin MS, Bontadi A, Hoxha A, De Carolis S, Botta A, Salvi S, Nuzzo M, Rovere-Querini P, Canti V, Mosca M, Mitic G, Bertero MT, Pengo V, Boffa MC, Tincani A.

Rheumatology (Oxford). 2011 Sep;50(9):1684-9.

Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study.

Ruffatti A, Del Ross T, Ciprian M, Bertero MT, Sciascia S, Scarpato S, Montecucco C, Rossi S, Caramaschi P, Biasi D, Doria A, Rampudda M, Monica N, Fischetti F, Picillo U, Brucato A, Salvan E, Vittorio P, Meroni P, Tincani A; Antiphospholipid Syndrome Study Group of Italian Society of Rheumatology.

Ann Rheum Dis. 2011 Jun;70(6):1083-6.

Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study.

Pisoni CN, Brucato A, Ruffatti A, Espinosa G, Cervera R, Belmonte-Serrano M, Sánchez-Román J, García-Hernández FG, Tincani A, Bertero MT, Doria A, Hughes GR, Khamashta MA.

Arthritis Rheum. 2010 Apr;62(4):1147-52.

Partecipazione a: APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking.www.ncbi.nlm.nih.gov/pubmed/22635205